PsiOxus Therapeutics Ltd.

PsiOxus is a clinical-stage company redefining therapies for solid tumors with the goal of curing patients with cancer. Our clinically validated, systemically dosed T-SIGn® viral vector platform delivers tumor-localized production of combinations of protein therapeutics and synthetic payloads within solid tumors. At PsiOxus, we are committed to unlocking the potential of immuno-oncology in solid tumors to improve survival rates for individuals battling cancer. Our team of business leaders, clinicians, research scientists, and other specialists are dedicated to developing new cancer treatments targeting unmet needs. Making a difference every day, with the goal of helping patients, is at the heart of what we do. PsiOxus aims to lead the world in tumor re-engineering, delivering medicines of significant benefit to patients with cancer.